Products
Platform
Research
Market
Learn
Compare DSP Healthcare Fund vs SBI Healthcare Opportunities Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | 4.0 | 5.0 |
Min SIP Amount | ₹100 | ₹500 |
Expense Ratio | 1.92 | 1.93 |
NAV | ₹39.69 | ₹435.81 |
Fund Started | 12 Nov 2018 | 04 Jun 1999 |
Fund Size | ₹3106.92 Cr | ₹3963.38 Cr |
Exit Load | Exit load of 0.50% if redeemed within 1 month. | Exit load of 0.50% if redeemed within 15 days |
Risk
Very High
Very High
Rating
4.0
5.0
Min SIP Amount
₹100
₹500
Expense Ratio
1.92
1.93
NAV
₹39.69
₹435.81
Fund Started
12 Nov 2018
04 Jun 1999
Fund Size
₹3106.92 Cr
₹3963.38 Cr
Exit Load
Exit load of 0.50% if redeemed within 1 month.
Exit load of 0.50% if redeemed within 15 days
Returns
1 Year | -2.74% | 3.61% |
3 Year | 23.50% | 26.15% |
5 Year | 19.07% | 20.80% |
1 Year
-2.74%
3.61%
3 Year
23.50%
26.15%
5 Year
19.07%
20.80%
Holding Analysis
Equity | 97.15% | 96.19% |
Cash | 2.85% | 3.74% |
Equity
97.15%
96.19%
Cash
2.85%
3.74%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Cipla Ltd. | 9.16% |
Sun Pharmaceutical Industries Ltd. | 7.88% |
Ipca Laboratories Ltd. | 7.56% |
Cohance Lifesciences Ltd. | 7.38% |
Laurus Labs Ltd. | 6.12% |
Gland Pharma Ltd. | 5.55% |
Apollo Hospitals Enterprise Ltd. | 4.77% |
Globus Medical Inc | 4.66% |
Illumina Inc. (USA) | 4.53% |
Sai Life Sciences Ltd. | 4.52% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 10.86% |
Divi's Laboratories Ltd. | 6.81% |
Max Healthcare Institute Ltd. | 6.12% |
Cipla Ltd. | 4.81% |
Lonza Group Ag | 4.24% |
Lupin Ltd. | 4.02% |
Torrent Pharmaceuticals Ltd. | 3.59% |
Mankind Pharma Ltd. | 3.49% |
Fortis Healthcare Ltd. | 3.45% |
Gland Pharma Ltd. | 3.31% |
Fund Manager
Name | Jay Kothari | Tanmaya Desai |
Start Date | 16 Mar 2018 | 27 Jun 2011 |
Name
Jay Kothari
Tanmaya Desai
Start Date
16 Mar 2018
27 Jun 2011
About Fund
Description | The scheme seeks to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies. | The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space. |
Launch Date | 12 Nov 2018 | 04 Jun 1999 |
Description
The scheme seeks to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies.
The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space.
Launch Date
12 Nov 2018
04 Jun 1999
